Literature DB >> 17675523

Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly.

Dirk Spitzer1, Lynne M Mitchell, John P Atkinson, Dennis E Hourcade.   

Abstract

Complement promotes the rapid recognition and elimination of pathogens, infected cells, and immune complexes. The biochemical basis for its target specificity is incompletely understood. In this report, we demonstrate that properdin can directly bind to microbial targets and provide a platform for the in situ assembly and function of the alternative pathway C3 convertases. This mechanism differs from the standard model wherein nascent C3b generated in the fluid phase attaches nonspecifically to its targets. Properdin-directed complement activation occurred on yeast cell walls (zymosan) and Neisseria gonorrhoeae. Properdin did not bind wild-type Escherichia coli, but it readily bound E. coli LPS mutants, and the properdin-binding capacity of each strain correlated with its respective serum-dependent AP activation rate. Moreover, properdin:single-chain Ab constructs were used to direct serum-dependent complement activation to novel targets. We conclude properdin participates in two distinct complement activation pathways: one that occurs by the standard model and one that proceeds by the properdin-directed model. The properdin-directed model is consistent with a proposal made by Pillemer and his colleagues >50 years ago.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17675523     DOI: 10.4049/jimmunol.179.4.2600

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  113 in total

1.  An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae.

Authors:  Sarika Agarwal; Viviana P Ferreira; Claudio Cortes; Michael K Pangburn; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

2.  Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis.

Authors:  Kaisa E Happonen; Tore Saxne; Anders Aspberg; Matthias Mörgelin; Dick Heinegård; Anna M Blom
Journal:  Arthritis Rheum       Date:  2010-12

3.  Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement.

Authors:  Viviana P Ferreira; Claudio Cortes; Michael K Pangburn
Journal:  Immunobiology       Date:  2010-02-12       Impact factor: 3.144

Review 4.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

5.  Native properdin binds to Chlamydia pneumoniae and promotes complement activation.

Authors:  Claudio Cortes; V P Ferreira; Michael K Pangburn
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

6.  Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury.

Authors:  Yuko Kimura; Lin Zhou; Takashi Miwa; Wen-Chao Song
Journal:  J Clin Invest       Date:  2010-10       Impact factor: 14.808

Review 7.  Complement: a key system for immune surveillance and homeostasis.

Authors:  Daniel Ricklin; George Hajishengallis; Kun Yang; John D Lambris
Journal:  Nat Immunol       Date:  2010-08-19       Impact factor: 25.606

Review 8.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

9.  Inhibition of complement activation on a model biomaterial surface by streptococcal M protein-derived peptides.

Authors:  Anna E Engberg; Kerstin Sandholm; Fredrik Bexborn; Jenny Persson; Bo Nilsson; Gunnar Lindahl; Kristina N Ekdahl
Journal:  Biomaterials       Date:  2009-01-25       Impact factor: 12.479

10.  Early complement factors in the local tissue immunocomplex generated during intestinal ischemia/reperfusion injury.

Authors:  Haekyung Lee; Danielle J Green; Lawrence Lai; Yunfang Joan Hou; Jens C Jensenius; David Liu; Cheolho Cheong; Chae Gyu Park; Ming Zhang
Journal:  Mol Immunol       Date:  2009-12-09       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.